Ian W. Flinn

54.2k total citations · 8 hit papers
542 papers, 18.8k citations indexed

About

Ian W. Flinn is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Ian W. Flinn has authored 542 papers receiving a total of 18.8k indexed citations (citations by other indexed papers that have themselves been cited), including 373 papers in Genetics, 296 papers in Pathology and Forensic Medicine and 158 papers in Oncology. Recurrent topics in Ian W. Flinn's work include Chronic Lymphocytic Leukemia Research (369 papers), Lymphoma Diagnosis and Treatment (295 papers) and CAR-T cell therapy research (85 papers). Ian W. Flinn is often cited by papers focused on Chronic Lymphocytic Leukemia Research (369 papers), Lymphoma Diagnosis and Treatment (295 papers) and CAR-T cell therapy research (85 papers). Ian W. Flinn collaborates with scholars based in United States, United Kingdom and Australia. Ian W. Flinn's co-authors include John C. Byrd, Michael R. Grever, Steven Coutré, R. Kanti, Brad S. Kahl, Richard R. Furman, Richard F. Ambinder, Richard A. Larson, Thomas J. Kipps and John C. Byrd and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Ian W. Flinn

524 papers receiving 18.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

2002 707 citations Ian W. Flinn, John C. Byrd et al. Blood profile →
ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic Leukemia

2004 659 citations John G. Gribben, Donna Neuberg et al. profile →
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

2016 563 citations Richard A. Larson, Ian W. Flinn et al. profile →
Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

2012 527 citations Ian W. Flinn et al. profile →
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

2014 465 citations Jennifer R. Brown, John C. Byrd et al. Blood profile →
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

2014 419 citations Ian W. Flinn, Richard van der Jagt et al. Blood profile →
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

2018 380 citations Alessandra Tedeschi, John G. Gribben et al. profile →
Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial

2025 42 citations Veronika Bachanová, Ian W. Flinn et al. profile →

Peers

Countries citing papers authored by Ian W. Flinn

Since Specialization

Citations

This map shows the geographic impact of Ian W. Flinn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian W. Flinn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian W. Flinn more than expected).

Fields of papers citing papers by Ian W. Flinn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ian W. Flinn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian W. Flinn. The network helps show where Ian W. Flinn may publish in the future.

Co-authorship network of co-authors of Ian W. Flinn

This figure shows the co-authorship network connecting the top 25 collaborators of Ian W. Flinn. A scholar is included among the top collaborators of Ian W. Flinn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ian W. Flinn. Ian W. Flinn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Fixed treatment duration subcutaneous mosunetuzumab monotherapy in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma: Interim results from the Phase II MorningSun study 2025 ·Blood ·Jeff P. Sharman, Aung M. Tun, José C. Villasboas, Ayed O. Ayed, (unknown), (unknown), Mei Wu, (unknown), Yong Mun, Vivek S. Chopra, (unknown), Jamal Misleh, Shachar Peles, Ian W. Flinn, John M. Burke	0
2	Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/ TP53 Mutation: SEQUOIA Arm D Results 2025 ·Journal of Clinical Oncology ·Mazyar Shadman, Talha Munir, Shuo Ma, Masa Lasica, Monica Tani, Tadeusz Robak, Ian W. Flinn, Jennifer R. Brown, Paolo Ghia, Emmanuelle Ferrant, Constantine S. Tam, Wojciech Janowski, Wojciech Jurczak, Linlin Xu, Tian Tian, Marcus Lefebure, (unknown), Jamie Hirata, Alessandra Tedeschi	3
3	Fixed-Duration Subcutaneous Mosunetuzumab Is Active and Has a Manageable Safety Profile in Patients with Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Updated Results from the Phase II Morningsun Study 2024 ·Blood ·John M. Burke, Ian W. Flinn, Lihua E. Budde, Aung M. Tun, Steven Liu, (unknown), (unknown), Mei Wu, Yong Mun, Vivek S. Chopra, Jessica M. Grindheim, (unknown), José C. Villasboas	2
4	Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study 2024 ·Journal of Clinical Oncology ·Lihua E. Budde, Sarit Assouline, Laurie H. Sehn, Stephen J. Schuster, Sung‐Soo Yoon, Dok Hyun Yoon, Matthew J. Matasar, Francesc Bosch, Won Seog Kim, Loretta J. Nastoupil, Ian W. Flinn, Mazyar Shadman, Catherine Diefenbach, Chan Y. Cheah, (unknown), Huang Huang, Antonia Kwan, Michael C. Wei, Shen Yin, Nancy L. Bartlett	34
5	A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies 2024 ·Clinical Cancer Research ·Pinkal Desai, Sagar Lonial, Amanda F. Cashen, Manali Kamdar, Ian W. Flinn, Susan O’Brien, Jacqueline S. Garcia, Neha Korde, Javid J. Moslehi, (unknown), (unknown), Shringi Sharma, (unknown), (unknown), (unknown), (unknown), Jamal Saeh, Marcio Andrade‐Campos, Tapan M. Kadia, James S. Blachly	15
6	Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial 2023 ·Annals of Oncology ·Anne‐Ségolène Cottereau, (unknown), Judith Trotman, Pierre Feugier, Loretta J. Nastoupil, Emmanuel Bachy, Ian W. Flinn, Corinne Haïoun, Loïc Ysebaert, Nancy L. Bartlett, Hervé Tilly, Olivier Casasnovas, Renato Pietro Ricci, (unknown), Irène Buvat, Michel Meignan, Franck Morschhauser	15
7	Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial 2023 ·Clinical Lymphoma Myeloma & Leukemia ·Matthew J. Matasar, Nancy L. Bartlett, Mazyar Shadman, Lihua E. Budde, Ian W. Flinn, Gareth P. Gregory, Won Seog Kim, Georg Heß, Dima El‐Sharkawi, Catherine Diefenbach, Huang Huang, Iris To, (unknown), (unknown), Antonia Kwan, Sarit Assouline	10
8	Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Patients with Relapsed or Refractory CD20+ B Cell Lymphoma 2023 ·Transplantation and Cellular Therapy ·Javier Muñoz, Ian W. Flinn, Jonathon B. Cohen, Jessica Sachs, (unknown), Ann Ranger, (unknown), Francis Payumo, Rajneesh Nath, Mehdi Hamadani, Jason R. Westin, Veronika Bachanová	2
9	A Phase 1 Dose Escalation Study of Igm-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies 2021 ·Blood ·Elizabeth Budde, Ajay K. Gopal, Won Seog Kim, Ian W. Flinn, Chan Y. Cheah, Loretta J. Nastoupil, Matthew J. Matasar, Catherine Diefenbach, Gareth P. Gregory, (unknown), (unknown), Maya K. Leabman, Genevive Hernandez, (unknown), Bruce A. Keyt, Daniel Chen, Philippe Armand	22
10	Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study 2020 ·Clinical Cancer Research ·John C. Byrd, Richard R. Furman, Steven Coutré, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Jeff P. Sharman, William G. Wierda, Weiqiang Zhao, Nyla A. Heerema, Ying Luan, Emily A. Liu, James P. Dean, Susan O’Brien	126
11	Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts 2020 ·Blood ·Matthew J. Matasar, Chan Y. Cheah, Dok Hyun Yoon, Sarit Assouline, Nancy L. Bartlett, Matthew Ku, Pratyush Giri, Anna Johnston, Ian W. Flinn, André Goy, Dimitrios Tzachanis, Carol O’Hear, Shen Yin, Iris To, (unknown), Chi‐Chung Li, Brendan C. Bender, Elicia Penuel, Huang Huang, Lihua E. Budde	27
12	The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma 2020 ·British Journal of Haematology ·Nathan Fowler, Loretta J. Nastoupil, Sven de Vos, Mark Knapp, Ian W. Flinn, Robert Chen, Ranjana H. Advani, Sumeet Bhatia, Peter Martin, Raul Mena, R. Eric Davis, Sattva S. Neelapu, Karl Eckert, Jerry Ping, (unknown), Darrin M. Beaupre, Jutta K. Neuenburg, M. Lia Palomba	20
13	Combination trial of duvelisib (IPI‐145) with rituximab or bendamustine/rituximab in patients with non‐Hodgkin lymphoma or chronic lymphocytic leukemia 2019 ·American Journal of Hematology ·Ian W. Flinn, Mohamad Cherry, Michael B. Maris, Jeffrey Matous, Jesús G. Berdeja, Manish R. Patel	33
14	Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 2017 ·Clinical Cancer Research ·Steven Coutré, Richard R. Furman, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Jeff P. Sharman, Jeffrey A. Jones, William G. Wierda, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, (unknown), Cathy Zhou, Elizabeth Bilotti, Danelle F. James, John C. Byrd, Susan O’Brien	47
15	Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies 2017 ·Blood ·Ian W. Flinn, Susan O’Brien, Brad S. Kahl, Manish R. Patel, Yasuhiro Oki, (unknown), Pierluigi Porcu, Jeffrey A. Jones, Jan A. Burger, Nitin Jain, Virginia Kelly, Kerstin Allen, Mark Douglas, Jennifer Sweeney, Patrick Kelly, Steven M. Horwitz	183
16	Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma 2017 ·Blood ·John Kuruvilla, Michael R. Savona, Rachid Baz, Morten Mau‐Sørensen, Nashat Gabrail, Ramiro Garzon, Richard M. Stone, Michael Wang, Lynn Savoie, Peter Martin, Ian W. Flinn, Meagan A. Jacoby, Thaddeus J. Unger, Jean-Richard Saint-Martin, Tami Rashal, Sharon Friedlander, Robert Carlson, Michael Kauffman, Sharon Shacham, Martin Gutierrez	112
17	Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study breakdown → 2014 ·Blood ·Ian W. Flinn, Richard van der Jagt, Brad S. Kahl, Peter Wood, Tim E. Hawkins, David MacDonald, Mark Hertzberg, Yiu‐Lam Kwan, David Simpson, Michael Craig, Kathryn S. Kolibaba, Samar Issa, Regina Clementi, Doreen M. Hallman, Mihaela Munteanu, Ling Chen, John M. Burke	419
18	Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E2997 2007 ·Journal of Clinical Oncology ·Michael R. Grever, David Lucas, Gordon W. Dewald, Donna Neuberg, John C. Reed, Shinichi Kitada, Ian W. Flinn, Martin S. Tallman, Frederick R. Appelbaum, Richard A. Larson, Elisabeth Paietta, Diane F. Jelinek, John G. Gribben, John C. Byrd	256
19	Phase III Trial of Fludarabine Plus Cyclophosphamide Compared With Fludarabine for Patients With Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997 2007 ·Journal of Clinical Oncology ·Ian W. Flinn, Donna Neuberg, Michael R. Grever, Gordon W. Dewald, John M. Bennett, Elisabeth Paietta, Mohamad A. Hussein, Frederick R. Appelbaum, Richard A. Larson, Dennis F. Moore, Martin S. Tallman	300
20	Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions 2004 ·Blood ·Gerard Lozanski, Nyla A. Heerema, Ian W. Flinn, Lisa Smith, (unknown), Jennifer Webb, Mollie E. Moran, Margaret S. Lucas, Thomas S. Lin, (unknown), John H. Proffitt, David Lucas, Michael R. Grever, John C. Byrd	306

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact